department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Boehringer Ingelheim Corp · catalysts · pharmadog

← back to Boehringer Ingelheim Corp

Catalysts for Boehringer Ingelheim Corp

113 tracked

SYNJARDY (EMPAGLIFLOZIN) — FDA approval

SYNJARDY (EMPAGLIFLOZIN) — FDA approval

SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + metformin hydrochloride ER)

SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + metformin hydrochloride ER)

CYLTEZO (ADALIMUMAB-ADBM) — FDA approval

CYLTEZO (ADALIMUMAB-ADBM) — FDA approval

SYNJARDY (EMPAGLIFLOZIN) — FDA approval

SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + metformin hydrochloride ER)

JARDIANCE (EMPAGLIFLOZIN) — FDA approval

TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + linagliptin + metformin hydrochloride) ER

SYNJARDY (EMPAGLIFLOZIN) — FDA approval

GLYXAMBI (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + linagliptin)

SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + metformin hydrochloride ER)

CYLTEZO (ADALIMUMAB-ADBM) — FDA approval

SPEVIGO (SPESOLIMAB-SBZO) — FDA approval

JARDIANCE (EMPAGLIFLOZIN) — FDA approval

SYNJARDY (EMPAGLIFLOZIN) — FDA approval

GLYXAMBI (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + linagliptin)

SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + metformin hydrochloride ER)

CYLTEZO (ADALIMUMAB-ADBM) — FDA approval

JARDIANCE (EMPAGLIFLOZIN) — FDA approval

CYLTEZO (ADALIMUMAB-ADBM) — FDA approval

JARDIANCE (EMPAGLIFLOZIN) — FDA approval

JARDIANCE (EMPAGLIFLOZIN) — FDA approval

JARDIANCE (EMPAGLIFLOZIN) — FDA approval

TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + linagliptin + metformin hydrochloride) ER

TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + linagliptin + metformin hydrochloride) ER

SYNJARDY (EMPAGLIFLOZIN) — FDA approval

SYNJARDY (EMPAGLIFLOZIN) — FDA approval

GLYXAMBI (EMPAGLIFLOZIN) — FDA approval

(empagliflozin + linagliptin)

← prevpage 2 of 4next →